ArticleInternational journal of cancer2013

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.

Erik Wennerberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.